GlobeNewsWire·5d ago
Amneal Announces FDA Approval and Launch of Lanreotide Injection- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production
Amneal's accelerating revenue growth, driven by biosimilar launches, has fueled significant gross margin expansion to 42.0% in 2026Q2 from 36.5% in 2025Q4, and operating leverage has lifted operating margin to 18.3%. However, the company's high leverage (total...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue grew 9.9% YoY to $796.2M in 2026Q2, with gross margin expanding to 42.0% and operating margin to 18.3%, reflecting a favorable mix shift toward higher-margin biosimilars.
AMRX stock shows strong performance with a notable 52-week high and significant trading volume, indicating investor confidence and market interest.
Comprehensive stock analysis, price targets, and earnings estimates are available for AMRX, providing investors with valuable insights for decision-making.
Amneal Pharmaceuticals is a key player in the pharmaceutical sector, with detailed stock quotes and historical data highlighting its market presence.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $0.30+34.8% vs $0.22 | $796M+3.6% vs $768M |
Q2 2026 May 7, 2026 | $0.27+58.8% vs $0.17 | $723M+0.4% vs $720M |
Q2 2026 Apr 22, 2026 | $0.27+58.8% vs $0.17 | $723M+0.4% vs $720M |
Q1 2026 Feb 27, 2026 | $0.21+16.7% vs $0.18 | $814M+0.9% vs $807M |
- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production
Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
On September 15, 2026, Amneal Pharmaceuticals Inc (AMRX) shares fell 3.3% to $16.65. This decline comes amid a 52-week trading range of $9.49 to $19.26, indicat
COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.
Benchmark AMRX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Amneal Pharmaceuticals, Inc. (AMRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $19.33 | $6.17B | 87.86 | 8.05% | 2.39% | 1208.4% | — | |
| $39.01 | $46.07B | 32.51 | 4.31% | 4.08% | 9.06% | — | |
| $17.12 | $19.94B | -5.71 | -2.98% | -2.79% | -2.79% | — | |
| $13.84 | $1.92B | -1.35 | -2.75% | -41.85% | -55.97% | — | |
| $34.10 | $1.38B | 28.66 | 27.37% | 6.57% | 28.67% | — | |
| $8.02 | $789.57M | -4.03 | — | — | -72.28% | — |
Amneal Pharmaceuticals, Inc. (AMRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Amneal Pharmaceuticals, Inc. (AMRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 10, 2026·SEC
Aug 3, 2026·SEC
Jul 31, 2026·SEC
Get notified when AMRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Amneal Pharmaceuticals, Inc. (AMRX) stock FAQ — growth, dividends, profitability & financials explained
Amneal Pharmaceuticals, Inc. (AMRX) reported $3.12B in revenue for fiscal year 2025. This represents a 260% increase from $866.3M in 2015.
Amneal Pharmaceuticals, Inc. (AMRX) grew revenue by 8.0% over the past year. This is steady growth.
Yes, Amneal Pharmaceuticals, Inc. (AMRX) is profitable, generating $157.4M in net income for fiscal year 2025 (2.4% net margin).
Amneal Pharmaceuticals, Inc. (AMRX) has a return on equity (ROE) of 1208.4%. This is excellent, indicating efficient use of shareholder capital.
Amneal Pharmaceuticals, Inc. (AMRX) generated $83.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
